We previously reported that short-term ibrutinib treatment (10 mg/kg, daily for 2 weeks, i.p.)reduces tau phosphorylation and suppresses tau kinase p-CDK5 levels without altering DYRK1A in a mouse model of AD [6, 7]. Here, MAPT is linked to Alzheimer disease.